We are live on ! Find out more
LABP

Landos Biopharma, Inc. Common Stock
LABP

Delisted

LABP was delisted on the 23rd of May, 2024.

Back to rankings

40 hedge funds and large institutions have $120M invested in Landos Biopharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

64% less capital invested

Capital invested by funds: $331M → $120M (-$211M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
12
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.49M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.68M
3
Morgan Stanley
Morgan Stanley
New York
+$1.6M
4
Walleye Capital
Walleye Capital
New York
+$1.11M
5
Two Sigma Investments
Two Sigma Investments
New York
+$576K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$3.11M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.82M
3
LGM
Logos Global Management
California
-$315K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$275K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$265K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$39K +$79.1K +753 +1,215%
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
$39K +$86.9K +827 New
AF
28
Allworth Financial
California
$25K – – –
TRCT
29
Tower Research Capital (TRC)
New York
$19K +$34.9K +332 +511%
UBS Group
30
UBS Group
Switzerland
$18K +$40K +381 New
Deutsche Bank
31
Deutsche Bank
Germany
$14K +$1.58K +15 +6%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$13K -$210 -2 -0.7%
AIG
33
American International Group
New York
$12K -$736 -7 -3%
Citigroup
34
Citigroup
New York
$12K +$20K +190 +345%
California State Teachers Retirement System (CalSTRS)
35
California State Teachers Retirement System (CalSTRS)
California
$8K -$10.1K -96 -38%
AIP
36
Ameritas Investment Partners
Nebraska
$2K – – –
Legal & General Group
37
Legal & General Group
United Kingdom
$2K – – –
CFA
38
Carroll Financial Associates
North Carolina
$2K +$210 +2 +5%
MCM
39
Manchester Capital Management
Vermont
$2K +$4.31K +41 New
WP
40
Woodline Partners
California
– -$3.11M -21,280 Closed
Ensign Peak Advisors
41
Ensign Peak Advisors
Utah
– -$1.82M -12,500 Closed
Cambridge Investment Research Advisors
42
Cambridge Investment Research Advisors
Iowa
– -$275K -1,883 Closed
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
– -$265K -1,817 Closed
GWM
44
Geneos Wealth Management
Colorado
– -$16K -110 Closed
CFA
45
Cahill Financial Advisors
Minnesota
– -$1K -10 Closed
Wells Fargo
46
Wells Fargo
California
– +$105 +1 New
1
2

LABP Hedge Fund Activity: Q4 2021 in Review

40 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q4 2021, worth a combined $120M — down 64% from $331M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new LABP positions and 6 closed out — a net gain of 5 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $2.49M. The largest seller was Woodline Partners, exiting entirely with an estimated $3.11M sold.

  • 40 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q4 2021, up from 35 in Q3 2021.
  • Funds reported $120M of Landos Biopharma, Inc. Common Stock stock for Q4 2021, down 64% quarter-over-quarter.
  • 11 funds opened new Landos Biopharma, Inc. Common Stock positions in Q4 2021 and 6 closed out, a net change of +5 holders.
  • The largest Landos Biopharma, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $2.49M added.
  • The largest Landos Biopharma, Inc. Common Stock seller in Q4 2021 was Woodline Partners, an estimated $3.11M sold.

Based on aggregated 13F filings for Q4 2021.